On June 14, 2023 T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, reported that the management will present virtually at the following upcoming healthcare conferences (Press release, T-Cure Bioscience, JUN 14, 2023, View Source;utm_medium=rss&utm_campaign=june-14-2023-t-cure-bioscience-announces-dr-gang-zeng-guest-speaker-at-two-upcoming-immunotherapy-summits-2 [SID1234632775]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

11th Annual Immuno-oncology Summit, August 7-9th in Boston

"Emerging Cell-based Immunotherapies" venue on Aug 8. Brochure PDF – https://immuno-oncologysummit.com/docs/librariesprovider48/brochures/23/Immuno-Oncology-Summit-Final-Brochure-2023.pdf

8th CAR-TCR Summit, Aug 29th-Sept 1st in Boston

"De-risking TCRs to Ensure Safety". Find out more here: View Source #CARTCR #immunotherapy #celltherapy #celltherapies #cellandgene #immunology